Market research
IPHA Innate Pharma
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 252M
- P/E ratio
- Not available
- Analyst target
- 7
- Dividend yield
- Not available
- Beta
- 0.86
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US45781K2042
- Market cap
- 252M
- P/E ratio
- Not available
- Analyst target
- 7
- Dividend yield
- Not available
- Beta
- 0.86
About
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the IPHA discussion.
5 years, 4 months ago
Innate Pharma S.A is currently in a long term downtrend where the price is trading 22.5% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.0.
Innate Pharma S.A's total revenue sank by 65.1% to $18M since the same quarter in the previous year.
Its net income has increased by 92.3% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 123.2% to $3M since the same quarter in the previous year.
Based on the above factors, Innate Pharma S.A gets an overall score of 3/5.